Abiopharma

🔍 Tel-Tzure Tlalit Bussi (Executive)

Company: IceCure Medical Ltd. (ICCM)

Report Date: 2026-08-14

Detailed Transactions and Holdings:

• Acquired 101,483 shares of Ordinary Shares (Direct)
  Date: 2026-08-14 | Code: A | equity_swap_involved: 0 | shares_owned_after: 106,518.00 | transaction_form_type: 4 | Footnotes: F1

Footnotes:

• F1: Represents (i) 101,483 restricted share units ("RSUs") granted on August 14, 2026, 25% of which vest on August 11, 2027, and the remaining 75% vest in twelve equal quarterly installments of 6.25% thereafter, (ii) 653 ordinary shares, (iii) 2,273 RSUs granted on July 2, 2024, 25% of which vested on July 29, 2026, and the remaining 75% vest in equal quarterly installments of 6.25% thereafter, (iv) 1,733 RSUs granted on November 5, 2025, 25% of which vest on November 5, 2026, and the remaining 75% vest in equal quarterly installments of 6.25% thereafter, and (v) 1,029 RSUs granted on March 16, 2026, 25% of which vest on March 16, 2027, and the remaining 75% vest in equal quarterly installments of 6.25% thereafter. Except for the 25% tranche of the RSUs granted on July 2, 2024 that vested on July 29, 2026, all of the foregoing RSUs remain unvested as of August 13, 2026. The holdings in clauses (ii) through (v) have been adjusted to reflect the Issuer's 1-for-30 reverse share split.